Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

ClinicalTrials.gov ID: NCT01781975

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01781975. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia with current technology, and thus they are at risk for devastating long-term complications. This phase II study is designed to evaluate the safety and efficacy of imatinib mesylate as a novel therapy for new-onset T1DM. Imatinib is a first-in-class tyrosine kinase inhibitor. This study will explore the potential role of short-term therapy with imatinib to induce tolerance and possibly lead to a durable long-term remission of T1DM.

Study identification

NCT ID: NCT01781975
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of California, San Francisco; Other
Enrollment: 67 participants

Conditions and interventions

Conditions

Interventions

Imatinib Mesylate Drug
Placebo (For imatinib mesylate) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 45 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2014 (Actual)
Primary completion: May 2017 (Actual)
Completion: May 2018 (Actual)
Last update posted: Feb 11, 2020

2014 – 2018

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California-San Francisco	San Francisco	California	94143	—
Barbara Davis Center	Aurora	Colorado	80045	—
Emory University	Atlanta	Georgia	30322	—
Indiana University	Indianapolis	Indiana	46202	—
University of Iowa	Iowa City	Iowa	52242	—
Joslin Diabetes Center	Boston	Massachusetts	02215	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
University of Texas Southwestern	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01781975, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 11, 2020 · Synced Nov 12, 2026